Abstract
Objective
To evaluate the effectiveness and safety of Baidu Jieduan Granules (BDJDG) to treat common type coronavirus disease 2019 (COVID-19).
Methods
This multicenter, retrospective, and observational clinical trial included 230 common COVID-19 patients in Leishenshan, Huangshi, and Laohekou Hospitals in Wuhan from January 21 to March 26, 2020. The included patients were further divided into two subgroups according to the use of supplemental oxygen, mild and moderate groups. During the first 14 d of hospitalization, all patients were administered BDJDG combined with conventional Western medicine, and observed for continuous 28 d. Primary outcomes were disease progression rate and discharge rate. Secondary outcomes included negative conversion time of nucleic acid, hospitalization duration, clinical symptom subsidence time, and symptom regression rate.
Results
A total of 230 common COVID-19 patients were analyzed (138 in moderate group and 92 in mild group). By day 28, the disease progression rate was 4.3% and the discharge rate was 95.7%. All mild cases recovered and were discharged from hospital. The median negative conversion time of nucleic acid of all 230 COVID-19 patients was 12 d [inter-quartile range (IQR) 3.5–17], the median hospitalization duration was 15 d (IQR 12–20). The median time to fever, cough, and fatigue recovery was 4 d (IQR 2–6), 8 d (IQR 5–12), and 8 d (IQR 5–11). The recovery rate of fever, cough, and fatigue was 94.6%, 90.5%, and 93.5%. The median time to clinical improvement was 12 d (IQR 10–17). Compared with the baseline, total leukocyte counts, neutrophil counts, lymphocyte counts, and platelet counts were increased significantly on days 7 and 14 (P<0.01). C-reactive protein markedly increased on day 3 and significantly decreased on days 7 and 14 (P<0.01). No serious adverse events occurred during treatment.
Conclusion
BDJDG may be effective and safe for treatment of common type COVID-19. (Registration No. ChiCTR2000030836)
Electronic Supplementary Material
Supplementary material (Appendices 1—4) is available in the online version of this article at 10.1007/s11655-022-3673-x.
Keywords: COVID-19, common type, Baidu Jieduan Granule, integrated Chinese and Western medicine
Supplementary material
Effectiveness and Safety of Baidu Jieduan Granules for COVID-19: A Retrospective Observational Multicenter Study
Author Contributions
Funding acquisition and supervision: Fang BJ; investigation: Xu XR, Zhang W, Wu XX; methodology: Huang TR, Zuo JG, Shao Z; software: Xu XR; writing-original draft: Xu XR; writing—review & editing: Fang BJ, Shuang Z.
Footnotes
Supported by the National Key Research and Development Program Project (No. 2018YFC1705900), and the Emergency Committee of the World Federation of Chinese Medicine Societies and Shanghai Society of Traditional Chinese Medicine and Shanghai Society of Traditional Chinese Medicine, Novel Coronavirus Pneumonia Emergency Tackling Key Project (No. SJZLJZ.N01)
Conflict of Interest
The authors have no conflicts of interest to declare.
Reference
- 1.World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed November 11, 2021.
- 2.The State Administration of Traditional Chinese Medicine Guidelines on diagnosis and treatment of novel coronavirus pneumonia (trial 8th edition) Chin J Viral Dis (Chin) 2020;10:321–328. [Google Scholar]
- 3.Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1342. doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]
- 4.Branch CMAR. Physicians CMDAR Guidelines for diagnosis, treatment and prevention of COVID-19 in Chinese adults. Natl Med J China. 2021;101:1293–1356. [Google Scholar]
- 5.Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25:1663–1669. doi: 10.26355/eurrev_202102_24877. [DOI] [PubMed] [Google Scholar]
- 6.Wang JB, Wang ZX, Jing J, Zhao P, Dong JH, Zhou YF, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med. 2020;26:648–655. doi: 10.1007/s11655-020-3426-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Xiong X, Wang P, Su K, Cho WC, Xing Y. Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis. Pharmacol Res. 2020;160:105056. doi: 10.1016/j.phrs.2020.105056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhang W, Fang BJ, Bu JH, Ye MQ, Wu XX, Sun ST, et al. Research on clinical application and mechanism of Jinhong Decotion in treatment of infectious diseases. J Basic Chin Med (Chin) 2021;27:298–301. [Google Scholar]
- 9.Yang R, Liu H, Bai C, Wang Y, Zhang X, Guo R, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res. 2020;157:104820. doi: 10.1016/j.phrs.2020.104820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Liang SB, Fang M, Liang CH, Lan HD, Shen C, Ya LJ, et al. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: a rapid systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2021;60:102744. doi: 10.1016/j.ctim.2021.102744. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Shi N, Liu B, Liang N, Ma Y, Ge Y, Yi H, et al. Association between early treatment with Qingfei Paidu Decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res. 2020;161:105290. doi: 10.1016/j.phrs.2020.105290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Deng X, Liu B, Li J, Zhang J, Zhao Y, Xu K. Blood biochemical characteristics of patients with coronavirus disease 2019 (COVID-19): a systemic review and meta-analysis. Clin Chem Lab Med. 2020;58:1172–1181. doi: 10.1515/cclm-2020-0338. [DOI] [PubMed] [Google Scholar]
- 14.Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Organization WH. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19. Accessed 11 August, 2021.
- 16.Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Canad Med Assoc J. 2020;192:E734–E44. doi: 10.1503/cmaj.200647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325:1185–1195. doi: 10.1001/jama.2021.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, et al. High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China. Front Immunol. 2021;12:627844. doi: 10.3389/fimmu.2021.627844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv 2020 [Epub ahead of print]. [DOI] [PMC free article] [PubMed]
- 20.Zhang L, Zheng X, Bai X, Wang Q, Chen B, Wang H, et al. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study. Phytomedicine. 2021;85:153531. doi: 10.1016/j.phymed.2021.153531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Li J, Ye Z, Gu HG, Cai B. Effect of serum inflammatory factors on rats with sepsis by Jinhong Decoction. Jilin J Chin Med (Chin) 2018;38:947–950. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Effectiveness and Safety of Baidu Jieduan Granules for COVID-19: A Retrospective Observational Multicenter Study